Alecsat is under clinical development by CytoVac and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Alecsat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Alecsat overview
Alecsat (autologous lymphoid effector cells specific against tumor-cells) is under development for the treatment of metastatic triple-negative breast cancer. The drug candidate is administered intravenously as a solution form. It is a cell-based therapy that contains tumor-specific cytotoxic lymphocytes (CTL) and natural killer (NK cells). It was also under development for glioblastoma multiforme, hormone-refractory prostate cancer, glioblastoma multiforme (naive and second line), malignant melanoma and pancreatic cancer.
CytoVac overview
CytoVac offers research, production, development, and distribution of cell-based cancer therapies. The company has developed cancer therapy ALECSAT an autologous cytotoxic T cells (CTL) and natural killer (NK) cell-based prostate cancer therapy based on the patient’s own immune system to fight cancer cells. Its clinical development program concentrates on different cancer forms such as prostate cancer, pancreas cancer, and glioblastoma brain cancer. CytoVac offers therapy treatment methods to blood cells and lymphocytes. The company also performs clinical trial programs for pancreatic cancer. It operates a research and production facility. CytoVac is headquartered in Horsholm, Denmark.
For a complete picture of Alecsat’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
